BACKGROUND: Minimally invasive parathyroidectomy (MIP) has become a well-accepted treatment for selected patients with primary hyperparathyroidism (PHPT). However, few studies have evaluated long-term outcomes for this operative approach. We therefore chose to examine both the long-term symptom resolution and biochemical cure following MIP for PHPT. METHODS: A total of 460 PHPT patients who underwent a MIP between 2004 and 2009 were successfully mailed a questionnaire that assessed preoperative and postoperative Parathyroidectomy Assessment of Symptoms (PAS) scores, most recent calcium and parathyroid hormone (PTH) levels, and information about any reoperation for PHPT. Long-term evaluation of symptomatic and biochemical cure was performed. RESULTS: A total of 200 patients (43.5%) responded to our correspondence. The mean age of the patients was 58.7 ± 11.9 years, 74.5% were female, and 78.5% were Caucasian. The mean follow-up was 37 ± 19 months. The mean PAS scores fell by 117 ± 14 at long-term follow-up after MIP (P < 0.0001). All 13 symptoms comprising the PAS score diminished, of which ten did so significantly (P < 0.01). There was a significant drop in the mean serum calcium (preop. 11.1 mg/dl, postop. 9.6 mg/dl; P < 0.0001) and PTH (preop. 130.9 pg/ml, postop. 45.7 pg/ml; P < 0.0001) at long-term follow-up. Five patients (2.5%) developed recurrent disease (calcium > 10.5 mg/dl), and one (0.5%) underwent a reoperation for persistent disease and was subsequently cured. CONCLUSIONS: This study demonstrates that MIP has long-term benefits in terms of excellent symptom resolution and a high biochemical cure rate (97%) in selected patients who have PHPT, preoperative localization with sestamibi scans, and assessment of intraoperative PTH level.
BACKGROUND: Minimally invasive parathyroidectomy (MIP) has become a well-accepted treatment for selected patients with primary hyperparathyroidism (PHPT). However, few studies have evaluated long-term outcomes for this operative approach. We therefore chose to examine both the long-term symptom resolution and biochemical cure following MIP for PHPT. METHODS: A total of 460 PHPT patients who underwent a MIP between 2004 and 2009 were successfully mailed a questionnaire that assessed preoperative and postoperative Parathyroidectomy Assessment of Symptoms (PAS) scores, most recent calcium and parathyroid hormone (PTH) levels, and information about any reoperation for PHPT. Long-term evaluation of symptomatic and biochemical cure was performed. RESULTS: A total of 200 patients (43.5%) responded to our correspondence. The mean age of the patients was 58.7 ± 11.9 years, 74.5% were female, and 78.5% were Caucasian. The mean follow-up was 37 ± 19 months. The mean PAS scores fell by 117 ± 14 at long-term follow-up after MIP (P < 0.0001). All 13 symptoms comprising the PAS score diminished, of which ten did so significantly (P < 0.01). There was a significant drop in the mean serum calcium (preop. 11.1 mg/dl, postop. 9.6 mg/dl; P < 0.0001) and PTH (preop. 130.9 pg/ml, postop. 45.7 pg/ml; P < 0.0001) at long-term follow-up. Five patients (2.5%) developed recurrent disease (calcium > 10.5 mg/dl), and one (0.5%) underwent a reoperation for persistent disease and was subsequently cured. CONCLUSIONS: This study demonstrates that MIP has long-term benefits in terms of excellent symptom resolution and a high biochemical cure rate (97%) in selected patients who have PHPT, preoperative localization with sestamibi scans, and assessment of intraoperative PTH level.
Authors: Janice L Pasieka; Louise L Parsons; Michael J Demeure; Stuart Wilson; Peter Malycha; Jean Jones; Beth Krzywda Journal: World J Surg Date: 2002-05-21 Impact factor: 3.352
Authors: William C Lavely; Sibyll Goetze; Kent P Friedman; Jeffrey P Leal; Zhe Zhang; Elizabeth Garret-Mayer; Alan P Dackiw; Ralph P Tufano; Martha A Zeiger; Harvey A Ziessman Journal: J Nucl Med Date: 2007-06-15 Impact factor: 10.057
Authors: Monica S Eigelberger; W Keat Cheah; Philip H G Ituarte; Leanne Streja; Quan-Yang Duh; Orlo H Clark Journal: Ann Surg Date: 2004-04 Impact factor: 12.969
Authors: Laura I Wharry; Linwah Yip; Michaele J Armstrong; Mohamed A Virji; Michael T Stang; Sally E Carty; Kelly L McCoy Journal: World J Surg Date: 2014-03 Impact factor: 3.352
Authors: T Weber; C Dotzenrath; H Dralle; B Niederle; P Riss; K Holzer; J Kußmann; A Trupka; T Negele; R Kaderli; E Karakas; F Weber; N Rayes; A Zielke; M Hermann; C Wicke; R Ladurner; C Vorländer; J Waldmann; O Heizmann; S Wächter; S Schopf; W Timmermann; D K Bartsch; R Schmidmaier; M Luster; K W Schmid; M Ketteler; C Dierks; P Schabram; T Steinmüller; K Lorenz Journal: Langenbecks Arch Surg Date: 2021-04-21 Impact factor: 3.445
Authors: Naykky M Singh Ospina; Rene Rodriguez-Gutierrez; Spyridoula Maraka; Ana E Espinosa de Ycaza; Sina Jasim; Ana Castaneda-Guarderas; Michael R Gionfriddo; Alaa Al Nofal; Juan P Brito; Patricia Erwin; Melanie Richards; Robert Wermers; Victor M Montori Journal: World J Surg Date: 2016-10 Impact factor: 3.352
Authors: F Saponaro; F Cetani; A Repaci; U Pagotto; C Cipriani; J Pepe; S Minisola; C Cipri; F Vescini; A Scillitani; A Salcuni; S Palmieri; C Eller-Vainicher; I Chiodini; B Madeo; E Kara; E Castellano; G Borretta; L Gianotti; F Romanelli; V Camozzi; A Faggiano; S Corbetta; L Cianferotti; M L Brandi; M L De Feo; A Palermo; G Vezzoli; F Maino; M Scalese; C Marcocci Journal: J Endocrinol Invest Date: 2018-04-03 Impact factor: 4.256
Authors: Naris Nilubol; Allison B Weisbrod; Lee S Weinstein; William F Simonds; Robert T Jensen; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Stephen Marx; Electron Kebebew Journal: World J Surg Date: 2013-08 Impact factor: 3.352